Siramesine, first developed as an antidepressant, is now being investigated for its potential in cancer treatment due to its anti-tumor properties. It works by inducing cell death, particularly in cancer cells, through a process called lysosomal membrane permeabilization and ferroptosis. It has also shown promise in combination with other cancer drugs to overcome drug resistance. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Siramesina and Siramesine free base. Its PubChem CID is 9829526.
Siramesine
| CAS No | 147817-50-3 |
|---|---|
| Molecular Formula | C30H31FN2O |
| Molecular Weight | 454.6 g/mol |
| Synonyms | 1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine] |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Siramesine, first developed as an antidepressant, is now being investigated for its potential in cancer treatment due to its anti-tumor properties. It works by inducing cell death, particularly in cancer cells, through a process called lysosomal membrane permeabilization and ferroptosis.
The listed CAS number is 147817-50-3.
The listed molecular formula is C30H31FN2O.
The listed molecular weight is 454.6 g/mol.
1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine].
The source lists Siramesina and Siramesine free base.